Evidence map›Paper›PMID 42703405›Full record

ArticleJournal of gastrointestinal oncology2026

Development and validation of a nomogram for the non-invasive prediction of human epidermal growth factor receptor 2 expression in gastric adenocarcinoma: an

Sijie Yang, Xiuqing Xue, Wen Jiang, Minyi Wang, Xinyi Zhang, Yu Chen, Dachuan Zhang, Qi Zhou, Yuetao Wang, Xiaoliang Shao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sijie Yang *Department of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Xiuqing Xue *Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Wen JiangDepartment of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Minyi WangDepartment of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Xinyi ZhangDepartment of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Yu ChenDepartment of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Dachuan ZhangDepartment of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Qi ZhouDepartment of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Yuetao WangDepartment of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Xiaoliang ShaoDepartment of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gastric cancer is a major global malignancy, and human epidermal growth factor receptor 2 (HER2) expression serves as a critical biomarker for guiding targeted treatment. However, current invasive biopsy methods have inherent limitations. This study aimed to explore the association between preoperative Methods: We retrospectively analyzed 231 gastric adenocarcinoma patients with preoperative Results: Of the 231 gastric adenocarcinoma patients enrolled, 30 (13%) were HER2-positive. Univariate logistic regression indicated positive correlations between HER2 positivity and higher primary tumor SUV Conclusions:

Indexed as

fluorodeoxyglucose (FDG)Gastric adenocarcinomahuman epidermal growth factor receptor 2 (HER2)nomogrampositron emission tomography (PET)

Identifiers

PMID42703405
PMCPMC13546557

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.